Profitability Ratios
| Ratio |
Value |
| GP Margin |
99.4% |
| EBIT Margin |
-98.2% |
| EBITDA Margin |
-97.0% |
| Operating Margin |
-98.2% |
| Pretax Margin |
-101.1% |
| Cont. Ops Margin |
-101.1% |
| Net Margin |
-101.1% |
| Bottom Line Margin |
-101.1% |
Liquidity Ratios
| Ratio |
Value |
| Current Ratio |
4.88 |
| Quick Ratio |
4.87 |
| Solvency Ratio |
-0.642 |
| Cash Ratio |
1.64 |
Valuation Ratios
| Ratio |
Value |
| Price/Earnings |
|
| PEG Ratio |
0.11 |
| Forward PEG |
0.11 |
| Price/Book |
3.88 |
| Price/Sales |
8.38 |
| Price/FCF |
-6.15 |
| Price/Op Cash Flow |
-6.15 |
Debt Ratios
| Ratio |
Value |
| Debt/Assets |
0.3364 |
| Debt/Equity |
0.5787 |
| Debt/Capital |
0.3666 |
| Long-Term Debt/Capital |
0.3148 |
| Financial Leverage |
1.72 |
Cash Flow Ratios
| Ratio |
Value |
| Working Capital Turnover |
0.35 |
| Operating Cash Flow Ratio |
-3.252 |
| Operating Cash Flow/Sales |
-136.2% |
| Free Cash Flow/Operating Cash Flow |
100.0% |
Coverage Ratios
| Ratio |
Value |
| Debt Service Coverage |
-3.31 |
| Interest Coverage |
-5.8653 |
| Short-Term Operating Cash Flow Coverage |
-10.88 |
| Operating Cash Flow Coverage |
-1.09 |
| Capital Expenditure Coverage |
0.00 |
| Dividend + Capital Expenditure Coverage |
0.00 |
Dividend Ratios
| Ratio |
Value |
| Payout Ratio |
0.0000% |
| Dividend Yield |
0.0000% |
| Dividend Yield % |
0.0000% |
| Dividend Per Share |
0.0000 |
Per Share Ratios
| Ratio |
Value |
| Revenue/Share |
0.14 |
| EPS |
-0.139 |
| Debt/Share |
0.1944 |
| Cash/Share |
0.27 |
| Book Value/Share |
0.30 |
| Tangible BV/Share |
0.17 |
| Equity/Share |
0.30 |
| Operating Cash Flow/Share |
-0.187 |
| Capital Expenditure/Share |
0.000 |
| FCF/Share |
-0.187 |
Other Ratios
| Ratio |
Value |
| Net Income/Earnings Before Tax |
1.000 |
| Earnings Before Tax/EBIT |
1.029 |
| Price/Fair Value |
3.88 |
| Debt/Market Cap |
0.1333 |
| Effective Tax Rate |
0.0% |
| Enterprise Value Multiple |
-9.22 |
LXRX - Lexicon Pharmaceuticals, Inc.